|
業務類別
|
Biotechnology |
|
業務概覽
|
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches. |
| 公司地址
| 1300 Rancho Conejo Boulevard, Suite 305, Thousand Oaks, CA, USA, 91320 |
| 電話號碼
| +1 805 716-2927 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.latigobio.com |
| 員工數量
| 59 |
| Mr. Todd N. Smith |
Director, President and Chief Executive Officer |
-- |
05/11/2026 |
| Ms. Neha Krishnamohan |
Principal Accounting Officer, Chief Financial Officer and Chief Business Officer |
-- |
17/07/2026 |
| Mr. Neil Singla, M.D. |
Chief Medical Officer |
美元 564.44K |
17/07/2026 |
|
|
| Dr. Beth C. Seidenberg,M.D. |
Director |
17/07/2026 |
| Mr. Timothy P. Walbert |
Chairman of the Board |
17/07/2026 |
| Mr. Todd N. Smith |
Director, President and Chief Executive Officer |
05/11/2026 |
| Mr. Kevin Raidy |
Independent Director |
17/07/2026 |
| Ms. Sara M. Bonstein |
Independent Director |
17/07/2026 |
| Mr. James Tananbaum, M.D. |
Director |
17/07/2026 |
| Mr. Deborah Palestrant, PhD |
Director |
17/07/2026 |
|
|
|
|